Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2022-09, Vol.173, p.285-296
Hauptverfasser:	Larkin, James, Weber, Jeffrey, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Marie, Middleton, Mark R., De la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A., Mandalá, Mario
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - adverse effects AJCC-8 criteria Clinical trials Criteria Distant metastases Effectiveness Humans Immunotherapy Ipilimumab Ipilimumab - adverse effects Melanoma Melanoma - drug therapy Melanoma - surgery Melanoma adjuvant therapy Melanoma, Cutaneous Malignant Metastases Monoclonal antibodies Neoplasm Staging Nivolumab Nivolumab - adverse effects Recurrence-free survival Skin Neoplasms - drug therapy Skin Neoplasms - surgery Stage 3 Statistical analysis Survival Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!